Dermatology

Host: Raj Chovatiya, MD, PhD

Guest: Tina Bhutani, MD, MAS

Oftentimes patients with skin of color are diagnosed with psoriasis at a later stage than Caucasian patients. There are also disparities in access to treatment and education. According to a recent study, some patients with skin of color were less willing to use certain medications to treat their psoriasis. To learn more, join Dr. Raj Chovatiya and Dr. Tina Bhutani, Associate Adjunct Professor of Dermatology at the University of California San Francisco School of Medicine and Owner of Synergy Dermatology in San Francisco.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Amy McMichael, MD

A recent study that looked at psoriasis in patients from different races and backgrounds found that there weren’t a significant number of differences in the factors studied between patients with skin of color and Caucasian patients. The one thing that was really quite impactful for patients who are Black is that they wanted to see more physicians who could speak to their cultural and ethnic backgrounds. So to learn more about the findings and how we can address these barriers, join Dr. Charles Turck as he dives in with Dr. Amy McMichael, Professor in the Department of Dermatology at Wake Forest School of Medicine in Winston-Salem, North Carolina.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Taylor Dickerson, MD

According to a recent study, patients with skin of color waited three times longer to be formally diagnosed with psoriasis and were almost four times more likely to be biopsied compared to non-Hispanic patients. And as a result, these patients were more likely to present with severe disease, greatly impacting their overall quality of life. To learn more about this study’s findings and how we can address racial disparities in psoriasis care, Dr. Charles Turck speaks with lead author Dr. Taylor Dickerson. Dr. Dickerson is a board-certified dermatologist and micrographic dermatologic surgeon at U.S. Dermatology Partners in Texas.

Guest: Andres Yarur, MD

It’s not uncommon for patients with inflammatory bowel disease (IBD) to have an overlapping immune-mediated condition like psoriasis, which is why it’s important to tailor therapy for these patients. Here to discuss the link between psoriasis and IBD and how this can affect our management approach is Dr. Andres Yarur, Associate Professor of Medicine at Cedars Sinai Medical Center in Los Angeles, California.

Host: Raj Chovatiya, MD, PhD

Guest: Steven R. Feldman, MD, PhD

According to recent studies, only about 50 percent of psoriasis patients are adherent to topical medications by the end of an eight-week treatment period. This can have a significant impact on a patient’s overall quality of life and outcomes, which is why Dr. Raj Chovatiya speaks with Dr. Steven Feldman about strategies to improve psoriasis patients’ adherence to topical agents. Dr. Feldman is a Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina

Guest: John Barbieri, MD, MBA, FAAD

Patients with psoriasis die about five years younger than those without the condition, and cardiovascular disease is the leading cause of this premature mortality. Tune in to hear Dr. John Barbieri discuss strategies to identify risk factors and improve cardiovascular disease prevention in patients with psoriasis. Dr. Barbieri is an Assistant Professor of Dermatology at Brigham and Women's Hospital at Harvard Medical School in Boston.

Host: Raj Chovatiya, MD, PhD

Guest: Jason E. Hawkes, MD, MS, FAAD

There are a few key points that dermatologists need to keep at the forefront of conversations to help bridge education gaps around psoriasis. One is to try and eliminate burdens that are deterring practitioners in dermatology from using highly effective and very safe medications. To learn more on how we can have a positive impact on education gaps and advocacy, join Dr. Raj Chovatiya as he speaks with Dr. Jason Hawkes, Medical Dermatologist in Sacramento, California.

Guest: Shari Lipner, MD

A recent study was conducted looking at initial therapies for newly diagnosed psoriasis patients by race. Prior studies have shown differences by race in terms of emerging treatments for different dermatological diseases, which have also shown differential biologic treatments based on race. To learn about the findings and how we can help fill this gap, join Dr. Shari Lipner, Associate Professor of Clinical Dermatology at Weill Cornell Medicine and co-author of the article, titled Racial Disparities in Primary Therapy for Newly Diagnosed Psoriasis Patients, which was published in the Journal of Drugs in Dermatology in July 2023.

Host: Jeffrey S. Weber, MD, PhD

This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.

Host: Sapna Patel, MD

This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.